Omega-3 and -6 Fatty Acids, Plasma - NBI
Omega-3 and -6 Fatty Acids, Plasma - NBI

Omega-3 and -6 Fatty Acids, Plasma

Regular price $92.00

This test provides health information that can be used to understand whether a person has enough omega-3 and omega-6 fatty acids, if they have too much of one or if the ratio of fatty acids is not optimal.

Among their roles in the body, omega-3 fatty acids are anti-inflammatory and omega-6 fatty acids promote inflammation. A common pro-inflammatory omega-6 fatty acid is arachidonic acid. Two anti-inflammatory omega-3 fatty acids are eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).

This test is used in clinical settings to provide a baseline and monitoring of individuals with cardiovascular disease (CVD). It’s used to identify people with low omega-3 levels who may be candidates for fatty acid supplementation, to monitor people on omega-3 supplementation to determine the effectiveness of the supplements, and to test for a potential role in risk reduction for non-CVD outcomes-aged related macular degeneration, RA, cancer, etc. (early data). Dietary changes and dietary supplements can change a person’s fatty acid profile and their disease risk.

What’s Reported
  • Arachidonic Acid
  • Docosahexaenoic Acid (DHA)
  • Eicosapentaenoic Acid (EPA)
  • EPA/Arachidonic Acid Ratio
  • Omega-3 (EPA+DHA) Index
  • Omega-6/Omega-3 Ratio

Methodology: Chromatography/Mass Spectrometry

Alternative names: Polyunsaturated Fatty Acids (PUFAs),EPA,Omega-3 Index,Omega-6/omega-3 Ratio,Phospholipid Omega-3 Fatty Acid,Arachidonic Acid/EPA Ratio,DHA,Arachidonic Acid (AA),Phospholipid Omega-6 Fatty Acid

How to prepare

Fasting: Fast for 10 to 12 hours, water only. No food.
Water: Drink plenty of water to stay well hydrated.
Medications: Take all medications as prescribed.
Dietary supplements: It’s recommended to avoid taking omega-3/omega-6 fatty acid dietary supplements (eg, fish oil), for two days prior to taking this test.

How long until you get the results

7-10 Business Days

Result turnaround times are estimates and not guaranteed. Due to factors outside of our control, such as weather, holidays, confirmation/repeat testing or equipment maintenance, our lab may require additional time to complete tests.

More about this test

While both types of fat are important for overall health, having too much omega-6 fatty acids promotes inflammation, a risk factor for heart disease, age-related macular degeneration, rheumatoid arthritis and some cancers. Chronic inflammation damages cells, weakens tissue and makes you age faster, a process called “inflammageing.” Inflammation is the link that ties together the most common diseases, including heart disease, diabetes, arthritis and obesity. Chronic inflammation may also be a general mechanism for several neurological diseases such as Alzheimer’s, Parkinson’s, depression, bipolar disorder, and multiple sclerosis.

Omega-3 and omega-6 fatty acids are part of a category of fats called long chain polyunsaturated fatty acids (PUFAs). These fats are incorporated into cell membranes and are important for cellular communications, membrane fluidity and genetic expression.

The central nervous system (the brain and spinal cord) is largely composed of fatty acids. Improving essential fatty acid status by eating fish or taking a fish oil supplement reduces the incidence of post-partum depression. Fatty-acid deficiencies have been implicated in many diseases, including obesity, cancer, heart disease, diabetes and autoimmune disorders such as rheumatoid arthritis and multiple sclerosis.

Additional Resources

Top Anti-inflammatory Foods, by Dr. John Neustadt

Omega-3 Fatty Acids: An Essential Contribution, Harvard School of Public Health
References

Ascherio A, Katan MB, Zock PL, Stampfer MJ, Willett WC. Trans fatty acids and coronary heart disease. N Engl J Med. Jun 24 1999;340(25):1994-1998. 

Chiu CC, Huang SY, Shen WW, Su KP. Omega-3 fatty acids for depression in pregnancy. Am J Psychiatry. Feb 2003;160(2):385. 

de Lorgeril M, Salen P. Alpha-linolenic acid and coronary heart disease. Nutr Metab Cardiovasc Dis. Jun 2004;14(3):162-169. 

De Vriese SR, Christophe AB, Maes M. Lowered serum n-3 polyunsaturated fatty acid (PUFA) levels predict the occurrence of postpartum depression: further evidence that lowered n-PUFAs are related to major depression. Life Sci. Nov 7 2003;73(25):3181-3187. 

Delarue J, LeFoll C, Corporeau C, Lucas D. N-3 long chain polyunsaturated fatty acids: a nutritional tool to prevent insulin resistance associated to type 2 diabetes and obesity? Reprod Nutr Dev. May-Jun 2004;44(3):289-299. 

Harris WS, Von Schacky C. The Omega-3 Index: a new risk factor for death from coronary heart disease? Prev Med. Jul 2004;39(1):212-220. 

Heller AR, Rossel T, Gottschlich B, et al. Omega-3 fatty acids improve liver and pancreas function in postoperative cancer patients. Int J Cancer. Sep 10 2004;111(4):611-616. 

Narayanan BA, Narayanan NK, Simi B, Reddy BS. Modulation of inducible nitric oxide synthase and related proinflammatory genes by the omega-3 fatty acid docosahexaenoic acid in human colon cancer cells. Cancer Res. Mar 1 2003;63(5):972-979. 

Rees AM, Austin MP, Parker G. Role of omega-3 fatty acids as a treatment for depression in the perinatal period. Aust N Z J Psychiatry. Apr 2005;39(4):274-280. 

Timonen M, Horrobin D, Jokelainen J, Laitinen J, Herva A, Rasanen P. Fish consumption and depression: the Northern Finland 1966 birth cohort study. J Affect Disord. Nov 1 2004;82(3):447-452. 

van Meeteren ME, Teunissen CE, Dijkstra CD, van Tol EA. Antioxidants and polyunsaturated fatty acids in multiple sclerosis. Eur J Clin Nutr. Dec 2005;59(12):1347-1361. 

Wang L, Folsom AR, Zheng ZJ, Pankow JS, Eckfeldt JH. Plasma fatty acid composition and incidence of diabetes in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Clin Nutr. Jul 2003;78(1):91-98. 

Zurier RB, Rossetti RG, Jacobson EW, et al. gamma-Linolenic acid treatment of rheumatoid arthritis. A randomized, placebo-controlled trial. Arthritis Rheum. 1996;39(11):1808-1817.